Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox extension in beta-thalassemia
NCT00171210Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2004
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of deferasirox in Transfusional Iron Overload (TIO), sponsored by Novartis. Primary endpoint: Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event up to 5 years. Started Oct 2004; status: completed.
02
Drugs
deferasirox
03
Conditions
Transfusional Iron Overload (TIO)
Beyond the preview
Go deeper on NCT00171210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171210.